Q1 Earnings Estimate for Immunovant Issued By Zacks Research

Immunovant, Inc. (NASDAQ:IMVT) – Equities research analysts at Zacks Research reduced their Q1 2026 EPS estimates for shares of Immunovant in a research report issued on Tuesday, January 7th. Zacks Research analyst E. Bagri now anticipates that the company will post earnings of ($0.82) per share for the quarter, down from their prior estimate of ($0.79). The consensus estimate for Immunovant’s current full-year earnings is ($2.73) per share. Zacks Research also issued estimates for Immunovant’s Q2 2026 earnings at ($0.87) EPS, Q3 2026 earnings at ($0.83) EPS, Q4 2026 earnings at ($0.85) EPS, FY2026 earnings at ($3.38) EPS, Q1 2027 earnings at ($0.87) EPS, Q2 2027 earnings at ($0.95) EPS, Q3 2027 earnings at ($0.90) EPS and FY2027 earnings at ($3.63) EPS.

A number of other analysts also recently weighed in on IMVT. Wells Fargo & Company reduced their target price on shares of Immunovant from $47.00 to $45.00 and set an “overweight” rating on the stock in a report on Thursday, December 19th. HC Wainwright restated a “buy” rating and issued a $51.00 target price on shares of Immunovant in a report on Friday, November 8th. Wolfe Research cut shares of Immunovant from an “outperform” rating to a “peer perform” rating in a research note on Friday, January 3rd. Oppenheimer lifted their price target on shares of Immunovant from $47.00 to $53.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 9th. Finally, Raymond James reaffirmed an “outperform” rating and set a $36.00 price target on shares of Immunovant in a research note on Thursday, October 10th. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, Immunovant has a consensus rating of “Moderate Buy” and an average target price of $47.22.

Immunovant Stock Down 0.6 %

Immunovant stock opened at $23.48 on Friday. The company’s 50-day moving average price is $27.07 and its 200-day moving average price is $28.59. Immunovant has a twelve month low of $23.08 and a twelve month high of $43.92. The company has a market cap of $3.45 billion, a PE ratio of -10.58 and a beta of 0.66.

Immunovant (NASDAQ:IMVT) last posted its earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). During the same period in the previous year, the company posted ($0.45) EPS.

Insider Buying and Selling at Immunovant

In related news, CEO Peter Salzmann sold 16,692 shares of the business’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $25.45, for a total transaction of $424,811.40. Following the completion of the transaction, the chief executive officer now owns 978,097 shares in the company, valued at $24,892,568.65. The trade was a 1.68 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Eva Renee Barnett sold 3,271 shares of the business’s stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $28.79, for a total transaction of $94,172.09. Following the transaction, the chief financial officer now owns 335,343 shares of the company’s stock, valued at approximately $9,654,524.97. This trade represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 77,247 shares of company stock valued at $2,034,425 in the last three months. Company insiders own 5.90% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. KBC Group NV increased its stake in shares of Immunovant by 46.2% in the third quarter. KBC Group NV now owns 1,936 shares of the company’s stock worth $55,000 after acquiring an additional 612 shares during the period. Quest Partners LLC lifted its holdings in Immunovant by 216.7% during the second quarter. Quest Partners LLC now owns 2,610 shares of the company’s stock valued at $69,000 after purchasing an additional 1,786 shares in the last quarter. Headlands Technologies LLC purchased a new position in Immunovant during the second quarter valued at $77,000. Assetmark Inc. lifted its holdings in Immunovant by 73.8% during the third quarter. Assetmark Inc. now owns 2,891 shares of the company’s stock valued at $82,000 after purchasing an additional 1,228 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of Immunovant by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,294 shares of the company’s stock valued at $148,000 after buying an additional 934 shares during the last quarter. Institutional investors and hedge funds own 47.08% of the company’s stock.

About Immunovant

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.